Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.
2 registered trials, newest registry update first. Showing only trials linked to Taldefgrobep alfa.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy NCT05337553 | Taldefgrobep alfa | Phase 3 | Active not recruiting | Biohaven Pharmaceuticals, Inc. | 269 | Sep 25, 2024 | Jun 1, 2026 |
| Taldefgrobep Alfa in Adults With Overweight and Obesity NCT07281495 | Taldefgrobep alfa | Phase 2 | Active not recruiting | Biohaven Therapeutics Ltd. | 150 | Sep 2026 | Mar 20, 2026 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.
